Skip to contentY
Yubo International Biotech Ltd
Y
YBGJYubo International Biotech Ltd Q1 2023 · 10-Q
Revenue$156.62K$156.62K+929.5% vs Q1 2022 Net Income-$316.67K-$316.67KN/M vs Q1 2022 EPS, diluted—
Gross Profit$57,690+597.9% Operating Income-$316,532N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Yubo International Biotech Ltd · CIK 895464 · Engraved from SEC EDGAR
Operating Cash Flow-$32,669N/M Free Cash Flowderived-$32,669N/M Margins · derivedGross margin36.8%−17.5 pt vs Q1 2022
Operating margin-202.1%+3603.4 pt vs Q1 2022
Net margin-202.2%+3603.4 pt vs Q1 2022
ended Mar 31, 2023 · filed May 15, 2023 · 45 d after period end